Market: Nasdaq Copenhagen
Symbol: GMAB
ISIN: DK0010272202/US3723032062
Industry : Health Care

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with core sites in Utrecht, the Netherlands and Princeton, New Jersey, U.S.

GMAB 20/05/2020
Currency DKK Number of Shares (mil) 65.28
Volume 241,389 Change (%) 2.68
Previous Close 2,028.00 Market Cap (mil) 132,388.03
GMAB 22/05/2020
Currency USD Number of Shares (mil) 650.47
Volume 241,668 Change (%) 0.86
Previous Close 29.30 Market Cap (mil) 1,912.71
Consolidated Key Figures (DKK million) 2016 2017 2018 2019
Revenue 1,816 2,365 3,025 5,366
Net result 1,187 1,104 1,472 2,166
Assets 5,238 6,603 8,461 15,144
Shareholders' equity 4,827 6,272 8,014 14,048
Basic net result per share (DKK) 19.83 18.14 24.03 34.40
Diluted net result per share (DKK) 19.22 17.77 23.73 34.03
Year-end share market price (DKK) 1,173.00 1,029.00 1,067.50 1,481.50
Price / book value 14.67 10.04 8.19 6.85
Shareholders' equity per share (DKK) 79.98 102.51 130.32 216.12
Equity ratio 92% 95% 95% 93%
Number of employees (FTE) at year-end 205 257 377 548